Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

Another win for opportunistic screening: AI turns head CT scans into heart assessments
AI can help care teams get additional value out of routine head CT images.
New data point to LAAO as a safe alternative to long-term drug therapy
At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.
Long-term antidepressant use may increase risk of sudden cardiac death
The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.
Outgoing SCAI president reflects on a busy year full of partnerships and advocacy
SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.
New data highlight an unexpected link between hypercortisolism and resistant hypertension
Clinicians may need to broaden their diagnostic approach when treating and managing patients with resistant hypertension.

Another win for opportunistic screening: AI turns head CT scans into heart assessments

AI can help care teams get additional value out of routine head CT images.

One of the big late-breaking trials presented at the 2026 American College of Cardiology (ACC) Scientific Sessions was the CHAMPION-AF, which showed left atrial appendage occlusion (LAAO) can offer a safe, non-drug alternative to anticoagulation therapy, even in patients with atrial fibrillation who are not at high risk for bleeding. First author of the study Shephal Doshi, MD, FACC, an electrophysiologist at Cedars Sinai Smidt Heart Institute, discussed the details of the trial. #LAAO #ACC #ACC26

New data point to LAAO as a safe alternative to long-term drug therapy

At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

Long-term antidepressant use may increase risk of sudden cardiac death

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

Video interview with Society for Cardiovascular Angiography and Interventions (SCAI) President Srihari S. Naidu, MD, FACC, FAHA, MSCAI, explains the advancements in interventional cardiology the society has championed over the past year. #SCAI

Outgoing SCAI president reflects on a busy year full of partnerships and advocacy

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months.

Deepak Bhatt discusses the MOMENTUM STUDY and the prevalence of hypercortisolism hypertension. #ACC #ACC26

New data highlight an unexpected link between hypercortisolism and resistant hypertension

Clinicians may need to broaden their diagnostic approach when treating and managing patients with resistant hypertension.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.